A Phase I,Randomized,Double Blinded,Placebo-controlled,Dose-escalating Study of the Safety,Tolerability and Pharmacokinetics of HMPL-689 in Healthy Volunteers

Trial Profile

A Phase I,Randomized,Double Blinded,Placebo-controlled,Dose-escalating Study of the Safety,Tolerability and Pharmacokinetics of HMPL-689 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs HMPL 689 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; First in man
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 31 Jul 2017 According to a Chi-Med media release, company expects to present dose escalation data from this trial in H2 2017 or H1 2018.
    • 16 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 21 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top